Search

Your search keyword '"DEL PRATO, Stefano"' showing total 312 results
Start Over Author "DEL PRATO, Stefano" Publisher american diabetes association
312 results on '"DEL PRATO, Stefano"'

5. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Author

Davies, Melanie J., primary, Aroda, Vanita R., additional, Collins, Billy S., additional, Gabbay, Robert A., additional, Green, Jennifer, additional, Maruthur, Nisa M., additional, Rosas, Sylvia E., additional, Del Prato, Stefano, additional, Mathieu, Chantal, additional, Mingrone, Geltrude, additional, Rossing, Peter, additional, Tankova, Tsvetalina, additional, Tsapas, Apostolos, additional, and Buse, John B., additional

Published
2022
Full Text
View/download PDF

14. Erratum. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care 2021;44:1062–1069

Author

Ahuja, Vasudha, primary, Aronen, Pasi, additional, Pramodkumar, T.A., additional, Looker, Helen, additional, Chetrit, Angela, additional, Bloigu, Aini H., additional, Juutilainen, Auni, additional, Bianchi, Cristina, additional, La Sala, Lucia, additional, Anjana, Ranjit Mohan, additional, Pradeepa, Rajendra, additional, Venkatesan, Ulagamadesan, additional, Jebarani, Sarvanan, additional, Baskar, Viswanathan, additional, Fiorentino, Teresa Vanessa, additional, Timpel, Patrick, additional, DeFronzo, Ralph A., additional, Ceriello, Antonio, additional, Del Prato, Stefano, additional, Abdul-Ghani, Muhammad, additional, Keinänen-Kiukaanniemi, Sirkka, additional, Dankner, Rachel, additional, Bennett, Peter H., additional, Knowler, William C., additional, Schwarz, Peter, additional, Sesti, Giorgio, additional, Oka, Rie, additional, Mohan, Viswanathan, additional, Groop, Leif, additional, Tuomilehto, Jaakko, additional, Ripatti, Samuli, additional, Bergman, Michael, additional, and Tuomi, Tiinamaija, additional

Published
2021
Full Text
View/download PDF

15. Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141

Author

Garofolo, Monia, primary, Gualdani, Elisa, additional, Bianchi, Cristina, additional, Aragona, Michele, additional, Campi, Fabrizio, additional, Lucchesi, Daniela, additional, Daniele, Giuseppe, additional, Miccoli, Roberto, additional, Francesconi, Paolo, additional, Del Prato, Stefano, additional, and Penno, Giuseppe, additional

Published
2021
Full Text
View/download PDF

16. Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis

Author

Ahuja, Vasudha, primary, Aronen, Pasi, additional, Pramodkumar, T.A., additional, Looker, Helen, additional, Chetrit, Angela, additional, Bloigu, Aini H., additional, Juutilainen, Auni, additional, Bianchi, Cristina, additional, La Sala, Lucia, additional, Anjana, Ranjit Mohan, additional, Pradeepa, Rajendra, additional, Venkatesan, Ulagamadesan, additional, Jebarani, Sarvanan, additional, Baskar, Viswanathan, additional, Fiorentino, Teresa Vanessa, additional, Timpel, Patrick, additional, DeFronzo, Ralph A., additional, Ceriello, Antonio, additional, Del Prato, Stefano, additional, Abdul-Ghani, Muhammad, additional, Keinänen-Kiukaanniemi, Sirkka, additional, Dankner, Rachel, additional, Bennett, Peter H., additional, Knowler, William C., additional, Schwarz, Peter, additional, Sesti, Giorgio, additional, Oka, Rie, additional, Mohan, Viswanathan, additional, Groop, Leif, additional, Tuomilehto, Jaakko, additional, Ripatti, Samuli, additional, Bergman, Michael, additional, and Tuomi, Tiinamaija, additional

Published
2021
Full Text
View/download PDF

19. Insulin as an early treatment for type 2 diabetes: origin or end of an old question?

Author

Del Prato, Stefano, Bianchi, Cristina, Dardano, Angela, and Miccoli, Roberto

Subjects
Cholesterol -- Health aspects, Diabetes therapy -- Health aspects, Mortality, Insulin -- Health aspects, Type 2 diabetes -- Drug therapy -- Health aspects, Health, European Association for the Study of Diabetes
Abstract

The Emerging Risk Factors Collaboration (1) has recently confirmed that type 2 diabetes remains associated with substantial premature mortality. Compared with nondiabetic individuals, those with diabetes have a hazard ratio [...]

Published
2013
Full Text
View/download PDF

20. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care editors' expert forum

Author

Raz, Itamar, Riddle, Matthew C., Rosenstock, Julio, Buse, John B., Inzucchi, Silvio E., Home, Philip D., Del Prato, Stefano, Ferrannini, Ele, Chan, Juliana C.N., Leiter, Lawrence A., LeRoith, Derek, DeFronzo, Ralph, and Cefalu, William T.

Subjects
Merck & Company Inc. -- Management, Johnson & Johnson -- Management, Bristol-Myers Squibb Co. -- Management, Pfizer Inc. -- Management, Novartis AG -- Management, AstraZeneca PLC -- Management, Eli Lilly and Co. -- Management, Sanofi S.A. -- Management, Diabetes therapy, Editors, Type 2 diabetes -- Care and treatment, Hyperglycemia -- Care and treatment, Pharmaceutical industry, Company business management, Health
Abstract

In June 2012, 13 thought leaders convened in a Diabetes Care Editors' Expert Forum to discuss the concept of personalized medicine in the wake of a recently published American Diabetes [...]

Published
2013
Full Text
View/download PDF

21. Pathogenetic mechanisms and cardiovascular risk: differences between [HbA.sub.1c] and oral glucose tolerance test for the diagnosis of glucose tolerance

Author

Bianchi, Cristina, Miccoli, Roberto, Bonadonna, Riccardo C., Giorgino, Francesco, Frontoni, Simona, Faloia, Emanuela, Marchesini, Giulio, Dolci, Maria A., Cavalot, Franco, Cavallo, Gisella M., Leonetti, Frida, and Del Prato, Stefano

Subjects
Glucose tolerance tests, Dextrose, Insulin resistance -- Research, Medical testing products, Insulin -- Research, Glucose, Cardiovascular diseases -- Research, Blood lipids, Health, American Diabetes Association
Abstract

OBJECTIVE--To ascertain to which extent the use of [HbA.sub.1c] and oral glucose tolerance test (OGTT) for diagnosis of glucose tolerance could identify individuals with different pathogenetic mechanisms and cardiovascular risk [...]

Published
2012
Full Text
View/download PDF

22. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study

Author

Garofolo, Monia, primary, Gualdani, Elisa, additional, Scarale, Maria Giovanna, additional, Bianchi, Cristina, additional, Aragona, Michele, additional, Campi, Fabrizio, additional, Lucchesi, Daniela, additional, Daniele, Giuseppe, additional, Miccoli, Roberto, additional, Francesconi, Paolo, additional, Del Prato, Stefano, additional, and Penno, Giuseppe, additional

Published
2020
Full Text
View/download PDF

25. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

Author

Nauck, Michael A., Del Prato, Stefano, Meier, Juris J., Duran-Garcia, Santiago, Rohwedder, Katja, Elze, Martina, and Parikh, Shamik J.

Subjects
Merck & Company Inc., Novartis Pharma AG, Bristol-Myers Squibb Co., Eli Lilly and Co., Sanofi S.A., European Association for the Study of Diabetes, Urinary tract infections -- Research -- Care and treatment -- Comparative analysis, Body weight -- Comparative analysis -- Research, Dextrose -- Comparative analysis -- Research, Diabetes therapy -- Comparative analysis -- Research, Glucose -- Comparative analysis -- Research, Clinical trials -- Comparative analysis -- Research, Type 2 diabetes -- Research -- Care and treatment -- Comparative analysis, Glipizide -- Research -- Comparative analysis, Pharmaceutical industry -- Comparative analysis -- Research, Health, Care and treatment, Research, Comparative analysis
Abstract

OBJECTIVE--Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin and may cause fewer of these adverse effects. We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy. RESEARCH DESIGN AND METHODS--This 52-week, double-blind, multicenter, active-controlled, noninferiority trial randomized patients with type 2 diabetes (baseline mean Hb[A.sub.1c], 7.7%), who were receiving metformin monotherapy, to add-on dapagliflozin (n = 406) or glipizide (n = 408) up-titrated over 18 weeks, based on glycemic response and tolerability, to ≤10 or ≤20 mg/day, respectively. RESULTS--The primary end point, adjusted mean Hb[A.sub.1c] reduction with dapagliflozin (--0.52%) compared with glipizide (-0.52%), was statistically noninferior at 52 weeks. Key secondary end points: dapagliflozin produced significant adjusted mean weight loss (-3.2 kg) versus weight gain (1.2 kg; P < 0.0001) with glipizide, significantly increased the proportion of patients achieving ≥5% body weight reduction (33.3%) versus glipizide (2.5%; P < 0.0001), and significantly decreased the proportion experiencing hypoglycemia (3.5%) versus glipizide (40.8%; P < 0.0001). Events suggestive of genital infections and lower urinary tract infections were reported more frequently with dapagliflozin compared with glipizide but responded to standard treatment and rarely led to study discontinuation. CONCLUSIONS--Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less hypoglycemia than glipizide in type 2 diabetes inadequately controlled with metformin. Long-term studies are required to further evaluate genital and urinary tract infections with SGLT2 inhibitors., Metformin is recommended as the initial oral antidiabetic drug (OAD) therapy for patients with type 2 diabetes (1-5), but the progressive nature of type 2 diabetes often requires treatment intensification [...]

Published
2011
Full Text
View/download PDF

26. Multidrug treatment of type 2 diabetes: a challenge for compliance

Author

Miccoli, Roberto, Penno, Giuseppe, and Del Prato, Stefano

Subjects
Diabetes therapy -- Research, Patient compliance -- Research, Diabetes -- Research, Antilipemic agents -- Research, Type 2 diabetes -- Research -- Drug therapy, Health
Abstract

Type 2 diabetes is a chronic and progressive condition associated with the risk of invalidating micro- and macrovascular complications. Hyperglycemia is the hallmark of the condition and, despite much discussion, [...]

Published
2011
Full Text
View/download PDF

27. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/ mortality? Yes

Author

Bianchi, Cristina, Miccoli, Roberto, Daniele, Giuseppe, Penno, Giuseppe, and Del Prato, Stefano

Subjects
Hypoglycemic agents -- Dosage and administration -- Research -- Complications and side effects, Cardiovascular diseases -- Risk factors -- Research -- Complications and side effects -- Drug therapy, Type 2 diabetes -- Drug therapy -- Complications and side effects -- Research -- Risk factors, Health
Abstract

A though type 2 diabetes is a heterogeneous condition encompassing multiple metabolic and vascular alterations, it can be easily described as a disease characterized by chronic hyperglycemia and increased cardiovascular [...]

Published
2009
Full Text
View/download PDF

28. Changing the treatment paradigm for type 2 diabetes

Author

Del Prato, Stefano, Penno, Giuseppe, and Miccoli, Roberto

Subjects
Diabetes therapy, Blood sugar, Type 2 diabetes -- Development and progression -- Care and treatment, Health, Care and treatment, Development and progression
Abstract

Based on the results of the U.K. Prospective Diabetes Study (UKPDS), '... treatment of type 2 diabetes [should] include aggressive efforts to lower blood glucose levels as close to normal [...]

Published
2009
Full Text
View/download PDF

29. Primary prevention of cardiovascular disease in people with dysglycemia

Author

Bianchi, Cristina, Miccoli, Roberto, Penno, Giuseppe, and Del Prato, Stefano

Subjects
Cholesterol -- Reports, Heart attack -- Prevention -- Reports, Prevalence studies (Epidemiology) -- Reports, Type 2 diabetes -- Prevention -- Reports, Health, Prevention, Reports
Abstract

Cardiovascular disease accounts for a great majority of deaths in patients with type 2 diabetes. According to the World Health Organization, the prevalence of cardiovascular disease in diabetic patients ranges [...]

Published
2008

30. Normal glucose tolerance and gestational diabetes mellitus: what is in between?

Author

Di Cianni, Graziano, Seghieri, Giuseppe, Lencioni, Cristina, Cuccuru, Ilaria, Anichini, Roberto, De Bellis, Alessandra, Ghio, Alessandra, Tesi, Federica, Volpe, Laura, and Del Prato, Stefano

Subjects
Glucose intolerance -- Health aspects -- Research -- Patient outcomes, Diabetes in pregnancy -- Patient outcomes -- Research -- Health aspects, Pregnancy, Complications of -- Patient outcomes -- Research -- Health aspects, Pregnant women -- Health aspects -- Research -- Patient outcomes, Health, Research, Patient outcomes, Health aspects
Abstract

OBJECTIVE--The aim of this article was to define the metabolic phenotype of pregnant women with one abnormal value (OAV) during an oral glucose tolerance test (OGTT) and to test whether [...]

Published
2007

31. An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast

Author

Piaggesi, Alberto, Macchiarini, Silvia, Rizzo, Loredana, Palumbo, Francesca, Tedeschi, Anna, Nobili, Laura Ambrosini, Leporati, Elisa, Scire, Vincenzo, Teobaldi, Ilaria, and Del Prato, Stefano

Subjects
Health
Abstract

OBJECTIVE--This study was designed to test the safety, effectiveness, and costs of offloading with a novel, off-the-shelf irremovable device in the management of diabetic foot ulceration (DFU). RESEARCH DESIGN AND [...]

Published
2007

32. The beneficial effects of pancreas transplant alone on diabetic nephropathy

Author

Coppelli, Alberto, Giannarelli, Rosa, Vistoli, Fabio, Del Prato, Stefano, Rizzo, Gaetano, Mosca, Franco, Boggi, Ugo, and Marchetti, Piero

Subjects
Pancreas -- Transplantation, Type 1 diabetes -- Care and treatment -- Research, Diabetic nephropathies -- Care and treatment -- Research, Health, Care and treatment, Research
Abstract

OBJECTIVE--Pancreas transplant alone can be effective in significantly improving the quality of life of type 1 diabetic patients, and it can also eliminate acute diabetes complications, such as hypoglycemic and/or [...]

Published
2005

33. Functional and molecular defects of pancreatic islets in human type 2 diabetes

Author

Del Guerra, Silvia, Lupi, Roberto, Marselli, Lorella, Masini, Matilde, Bugliani, Marco, Sbrana, Simone, Torri, Scilla, Pollera, Maria, Boggi, Ugo, Mosca, Franco, Del Prato, Stefano, and Marchetti, Piero

Subjects
Diabetes -- Research, Insulin resistance -- Research -- Risk factors -- Diagnosis, Cardiovascular diseases -- Risk factors -- Research -- Diagnosis, Type 2 diabetes -- Diagnosis -- Risk factors -- Research, Health, Diagnosis, Research, Risk factors
Abstract

To shed further light on the primary alterations of insulin secretion in type 2 diabetes and the possible mechanisms involved, we studied several functional and molecular properties of islets isolated from the pancreata of 13 type 2 diabetic and 13 matched nondiabetic cadaveric organ donors. Glucose-stimulated insulin secretion from type 2 diabetic islets was significantly lower than from control islets, whereas arginine- and glibenclamide-stimulated insulin release was less markedly affected. The defects were accompanied by reduced mRNA expression of GLUT1 and -2 and glucokinase and by diminished glucose oxidation. In addition, AMP-activated protein kinase activation was reduced. Furthermore, the expression of insulin was decreased, and that of pancreatic duodenal homeobox-1 (PDX-1) and forkhead box O1 (Foxo-1) was increased. Nitrotyrosine and 8-hydroxy-2'-deoxyguanosine concentrations, markers of oxidative stress, were significantly higher in type 2 diabetic than control islets, and they were correlated with the degree of glucose-stimulated insulin release impairment. Accordingly, 24-h exposure to glutathione significantly improved glucose-stimulated insulin release and decreased nitrotyrosine concentration, with partial recovery of insulin mRNA expression. These results provide direct evidence that the defects of insulin secretion in type 2 diabetic islets are associated with multiple islet cell alterations. Most importantly, the current study shows that the functional impairment of type 2 diabetic islets can be, at least in part, reversible. In this regard, it is suggested that reducing islet cell oxidative stress is a potential target of human type 2 diabetes therapy., Diabetes is a chronic metabolic syndrome caused by insulin deficiency. There are ~200 million diabetic individuals in the world, with only about half being diagnosed, and these numbers are expected [...]

Published
2005

34. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief

Author

Piaggesi, Alberto, Viacava, Paolo, Rizzo, Loredana, Naccarato, Giuseppe, Baccetti, Fabio, Romanelli, Marco, Zampa, Virna, and Del Prato, Stefano

Subjects
Care and treatment, Complications and side effects, Development and progression, Research, Diabetes mellitus -- Care and treatment -- Development and progression -- Complications and side effects -- Research, Pathological histology -- Research, Diabetic foot -- Development and progression -- Care and treatment -- Research -- Complications and side effects, Diabetes -- Care and treatment -- Development and progression -- Complications and side effects -- Research, Histology, Pathological -- Research
Abstract

OBJECTIVE--This study was designed to evaluate the histopathology of neuropathic ulcers and whether pressure relief could change such histological patterns. RESEARCH DESIGN AND METHODS--We compared neuropathic plantar ulcers tissue excised [...]

Published
2003

35. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis

Author

Del Prato, Stefano, Heine, Robert J., Keilson, Leonard, Guitard, Christiane, Shen, Sharon G., and Emmons, Rebecca P.

Subjects
Aged patients -- Drug therapy -- Care and treatment -- Patient outcomes, Kidney failure -- Care and treatment -- Drug therapy -- Patient outcomes, Type 2 diabetes -- Drug therapy -- Patient outcomes -- Care and treatment, Nateglinide -- Health aspects, Health, Drug therapy, Care and treatment, Patient outcomes, Health aspects
Abstract

OBJECTIVE--To evaluate the impact of renal impairment (RI) (estimated creatinine clearance [[Cl.sub.cr]] RESEARCH DESIGN AND METHODS--Retrospective subgroup analyses were performed on pooled data from all completed nateglinide studies (12 randomized, [...]

Published
2003

36. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. (Brief Genetics Report)

Author

Sesti, Giorgio, Cardellini, Marina, Marini, Maria Adelaide, Frontoni, Simona, D'Adamo, Monica, Del Guerra, Silvia, Lauro, Davide, De Nicolais, Pierluigi, Sbraccia, Paolo, Del Prato, Stefano, Gambardella, Sergio, Federici, Massimo, Marchetti, Piero, and Lauro, Renato

Subjects
Type 2 diabetes -- Genetic aspects -- Development and progression, Health, Development and progression, Genetic aspects
Abstract

It was reported that the common -866G/A polymorphism in the promoter of the human uncoupling protein-2 (UCP2) gene, which enhances its trascriptional activity, is associated with increased mRNA levels in human adipocytes and reduced risk of obesity. Studies in knockout mice and β-cells indicate that UCP2 may play a role in β-cell function. In this study, we addressed the question of whether the common -866G/A polymorphism in UCP2 gene contributes to the variation of insulin secretion in humans by genotyping 301 nondiabetic subjects who underwent an oral glucose tolerance test. Glucose-stimulated insulin secretion estimated by several indexes of β-cell function was significantly lower in carriers of the -866A/A genotype compared with -866A/G or -866G/G according to the dosage of the A allele (P = 0.002-0.05). To investigate directly whether the UCP2 -866G/A polymorphism affects human islet function, pancreatic islets isolated from two -866G/G homozygous, seven -866G/A heterozygous, and one--866A/A homozygous nondiabetic donors were studied. Islets from -866A/A homozygous had lower insulin secretion in response to glucose stimulation as compared with -866G/G and -866G/A carriers. These results indicate that the common--866G/A polymorphism in the UCP2 gene may contribute to the biological variation of insulin secretion in humans., The pathophysiology of type 2 diabetes includes two distinct defects: impaired insulin action in peripheral tissues and a failure of pancreatic B-cells to compensate for the enhanced insulin demand by [...]

Published
2003

37. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated

Author

Lupi, Roberto, Dotta, Francesco, Marselli, Lorella, Del Guerra, Silvia, Masini, Matilde, Santangelo, Carmela, Patane, Giovanni, Boggi, Ugo, Piro, Salvatore, Anello, Marcello, Bergamini, Ettore, Mosca, Franco, Di Mario, Umberto, Del Prato, Stefano, and Marchetti, Piero

Subjects
Diabetes -- Research, Pancreatic beta cells -- Physiological aspects -- Research, Fatty acids -- Physiological aspects -- Research, Health, Physiological aspects, Research
Abstract

In an effort to better understand the phenomenon of lipotoxicity in human β-cells, we evaluated the effects of 48-h preculture with 1.0 or 2.0 mmol/l free fatty acid (FFA) (2:1 [...]

Published
2002

38. Insulin secretory function is impaired in isolated human islets carrying the [Gly.sup.972] → Arg IRS-1 polymorphism. (Brief Genetics Report)

Author

Marchetti, Piero, Lupi, Roberto, Federici, Massimo, Marselli, Lorella, Masini, Matilde, Boggi, Ugo, Del Guerra, Silvia, Patane, Giovanni, Piro, Salvatore, Anello, Marcello, Bergamini, Ettore, Purrello, Francesco, Lauro, Renato, Mosca, Franco, Sesti, Giorgio, and Del Prato, Stefano

Subjects
Islands of Langerhans -- Physiological aspects -- Genetic aspects, Genetic polymorphisms -- Physiological aspects -- Genetic aspects, Type 2 diabetes -- Genetic aspects, Health, Physiological aspects, Genetic aspects
Abstract

Type 2 (non-insulin-dependent) diabetes results from decreased insulin action in peripheral target tissues (insulin resistance) and impaired pancreatic β-cell function. These defects reflect both genetic components and environmental risk factors. [...]

Published
2002

39. Lipotoxicity in human pancreatic islets and the protective effect of metformin

Author

Lupi, Roberto, Del Guerra, Silvia, Fierabracci, Vanna, Marselli, Lorella, Novelli, Michela, Patane, Giovanni, Boggi, Ugo, Mosca, Franco, Piro, Salvatore, Del Prato, Stefano, and Marchetti, Piero

Subjects
Biological transport -- Research -- Physiological aspects, Diabetes -- Research, Pancreas -- Secretions, Metformin -- Physiological aspects -- Research, Insulin -- Research, Type 2 diabetes -- Research, Health, Physiological aspects, Research
Abstract

Human pancreatic islets from eight donors were incubated for 48 h in the presence of 2.0 mmol/l free fatty acid (FFA) (oleate to palmitate, 2 to 1). Insulin secretion was [...]

Published
2002

40. Phasic insulin release and metabolic regulation in type 2 diabetes

Author

Del Prato, Stefano, Marchetti, Piero, and Bonadonna, Riccardo C.

Subjects
Biological transport -- Research -- Physiological aspects, Pancreas -- Secretions, Diabetes -- Research, Insulin resistance -- Physiological aspects -- Research, Insulin -- Research, Glucose metabolism -- Physiological aspects -- Research, Type 2 diabetes -- Research, Health, Physiological aspects, Research
Abstract

Type 2 diabetes is a heterogeneous disorder due to prevalent insulin resistance associated with deficient insulin secretion or to a prevalent defect of insulin secretion associated with impaired insulin action. [...]

Published
2002

41. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial

Author

Blonde, Lawrence, primary, Rosenstock, Julio, additional, Del Prato, Stefano, additional, Henry, Robert, additional, Shehadeh, Naim, additional, Frias, Juan, additional, Niemoeller, Elisabeth, additional, Souhami, Elisabeth, additional, Ji, Chen, additional, and Aroda, Vanita R., additional

Published
2019
Full Text
View/download PDF

42. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria

Author

Trevisan, Roberto, Bruttomesso, Daniela, Vedovato, Monica, Brocco, Stefano, Pianta, Alessandro, Mazzon, Cinzia, Girardi, Carlo, Jori, Elisabetta, Semplicini, Andrea, Tiengo, Antonio, and Del Prato, Stefano

Subjects
Sodium in the body -- Physiological aspects, Type 1 diabetes -- Physiological aspects, Insulin resistance -- Physiological aspects, Albuminuria -- Physiological aspects, Health, Physiological aspects
Abstract

We assessed blood pressure (BP), body weight, renal hemodynamics, and insulin sensitivity (by euglycemic-hyperinsulinemic clamp) in nine normoalbuminuric and seven microalbuminuric IDDM patients after 6 days on a low-sodium diet [...]

Published
1998

44. Bedtime insulin daytime glipizide: effective therapy for sulfonylurea failures in NIDDM

Author

Shank, Myron L., Del Prato, Stefano, and DeFronzo, Ralph A.

Subjects
Type 2 diabetes -- Drug therapy, Health, Drug therapy
Abstract

Bedtime insulin (BI)/daytime sulfonylurea (DSU) therapy was studied double-blind in 30 non-insulin-dependent diabetes mellitus subjects in whom sulfonylurea (SU) therapy had failed. Subjects were switched to glipizide for 2 months [...]

Published
1995

45. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction

Author

Nicolucci, Antonio, Del Prato, Stefano, and Vespasiani, Giacomo

Subjects
Diabetes therapy, Patient satisfaction, Diabetes -- Research, Insulin -- Dosage and administration, Blood sugar, Type 2 diabetes -- Care and treatment, Diabetics -- Surveys -- Care and treatment, Health
Abstract

OBJECTIVE--To determine the functional health status and treatment satisfaction in patients with type 2 diabetes from the Evaluation of Lantus Effect ON Optimization of use of single dose Rapid insulin [...]

Published
2011
Full Text
View/download PDF

46. In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension

Author

Bonora, Enzo, Bonadonna, Riccardo C., Del Prato, Stefano, Gulli, Giovanni, Solini, Anna, Matsuda, Masafumi, and DeFronzo, Ralph A.

Subjects
Obesity -- Physiological aspects -- Complications and side effects, Insulin resistance -- Causes of -- Complications and side effects, Glucose metabolism -- Physiological aspects, Type 2 diabetes -- Complications and side effects, Hypertension -- Complications and side effects, Health, Physiological aspects, Complications and side effects, Causes of
Abstract

This study examined whether the presence of hypertension, an insulin-resistant condition, exacerbates the defect in insulin action observed in obesity and type II diabetes mellitus. Glucose metabolism in the basal [...]

Published
1993

47. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women

Author

Bonora, Enzo, Del Prato, Stefano, Bonadonna, Riccardo C., Gulli, Giovanni, Solini, Ann, Shank, Myron L., Ghiatas, Abraham A., Lancaster, Jack L., Kilcoyne, Raphael F., Alyassin, Abdalmajeid M., and DeFronzo, Ralph A.

Subjects
Women -- Physiological aspects, Obesity -- Physiological aspects, Adipose tissues -- Physiological aspects, Glucose metabolism -- Physiological aspects, Health, Physiological aspects
Abstract

In this study, total body fat content and fat topography were related to glucose metabolism in the basal and insulin-stimulated states in 18 nonobese and 18 obese premenopausal nondiabetic women. [...]

Published
1992

48. Ketone body metabolism in NIDDM: effect of sulfonylurea treatment

Author

Avogaro, Angelo, Valerio, Anna, Gnudi, Luigi, Maran, Alberto, Zolli, Mario, Duner, Elena, Riccio, Antonio, Del Prato, Stefano, Tiengo, Antonio, and Nosadini, Romano

Subjects
Hypoglycemic sulfonylureas -- Health aspects -- Physiological aspects, Ketones -- Physiological aspects -- Health aspects, Sulfonylurea compounds -- Health aspects -- Physiological aspects, Type 2 diabetes -- Care and treatment, Health, Care and treatment, Physiological aspects, Health aspects
Abstract

We assessed the metabolism of the two KBs, AcAc and 3-BOH; the relationships between ketogenesis and FFA inflow rate; and the effect of chronic sulfonylurea treatment in mild NIDDM patients [...]

Published
1992

49. How do we define cure of diabetes? (CONSENSUS STATEMENT: Reviews/Commentaries/ADA Statements)

Author

Buse, John B., Caprio, Sonia, Cefalu, William T., Ceriello, Antonio, Del Prato, Stefano, Inzucchi, Silvio E., McLaughlin, Sue, Phillips, II, Gordon L., Robertson, R. Paul, Rubino, Francesco, Kahn, Richard, and Kirkman, M. Sue

Subjects
American Diabetes Association, Obesity -- Surgery, Type 2 diabetes -- Care and treatment, Health, Care and treatment
Abstract

The mission of the American Diabetes Association is 'to prevent and cure diabetes and to improve the lives of all people affected by diabetes.' Increasingly, scientific and medical articles (1) [...]

Published
2009
Full Text
View/download PDF

50. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study.

Author

Coppelli, Alberto, Giannarelli, Rosa, Aragona, Michele, Penno, Giuseppe, Falcone, Marco, Tiseo, Giusy, Ghiadoni, Lorenzo, Barbieri, Greta, Monzani, Fabio, Virdis, Agostino, Menichetti, Francesco, Del Prato, Stefano, Sabrina, Agostini o Degl'Innocenti, Rachele, Antognoli, Rubia, Baldassarri, Pietro, Bertini, Martina, Biancalana, Matteo, Borselli, Giulia, Brizzi, and Valeria, Calsolario

Subjects
COVID-19, HYPERGLYCEMIA, HOSPITAL admission & discharge, DIABETES complications, VIRAL pneumonia, PROGNOSIS, DIABETES, BLOOD sugar, SEVERITY of illness index, HOSPITAL care, EPIDEMICS, DISEASE complications
Abstract

Objective: To explore whether at-admission hyperglycemia is associated with worse outcomes in patients hospitalized for coronavirus disease 2019 (COVID-19).Research Design and Methods: Hospitalized COVID-19 patients (N = 271) were subdivided based on at-admission glycemic status: 1) glucose levels <7.78 mmol/L (NG) (N = 149 [55.0%]; median glucose 5.99 mmol/L [range 5.38-6.72]), 2) known diabetes mellitus (DM) (N = 56 [20.7%]; 9.18 mmol/L [7.67-12.71]), and 3) no diabetes and glucose levels ≥7.78 mmol/L (HG) (N = 66 [24.3%]; 8.57 mmol/L [8.18-10.47]).Results: Neutrophils were higher and lymphocytes and PaO2/FiO2 lower in HG than in DM and NG patients. DM and HG patients had higher D-dimer and worse inflammatory profile. Mortality was greater in HG (39.4% vs. 16.8%; unadjusted hazard ratio [HR] 2.20, 95% CI 1.27-3.81, P = 0.005) than in NG (16.8%) and marginally so in DM (28.6%; 1.73, 0.92-3.25, P = 0.086) patients. Upon multiple adjustments, only HG remained an independent predictor (HR 1.80, 95% CI 1.03-3.15, P = 0.04). After stratification by quintile of glucose levels, mortality was higher in quintile 4 (Q4) (3.57, 1.46-8.76, P = 0.005) and marginally in Q5 (29.6%) (2.32, 0.91-5.96, P = 0.079) vs. Q1.Conclusions: Hyperglycemia is an independent factor associated with severe prognosis in people hospitalized for COVID-19. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results